Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Teams Up with Ortho-Clinical to Turn Biomarkers into Dx

NEW YORK, June 8 (GenomeWeb News) - Compugen and Ortho-Clinical Diagnostics, a Johnson & Johnson company, will jointly develop diagnostic tests based on Compugen's biomarkers, the Tel Aviv-based company said today.


Initially, Ortho-Clinical will have the option to select up to nine biomarkers that the partners will clinically validate. Following successful validation, Ortho-Clinical plans to develop markers into products. In exchange for paying development milestones and revenue-based royalties, Ortho-Clinical will have worldwide rights to commercialize the tests. Compugen will also receive license fees for each commercialized biomarker.


Compugen discovered the biomarkers using its LEADS platform, which analyzes the human proteome.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.